Kinfo
Advanced Biomed Inc. logo

Advanced Biomed Inc.

ADVBNASDAQHealthcare·US · USD
$5.16
-0.16 (-3.10%)
Prices as of July 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap8.53M USD
Enterprise value5.46M USD
Trailing P/E1.33
Forward P/E0.00
PEG ratio0.00
Price / sales0.00
Price / book0.80
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-21.50%
Return on equity71.33%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-2.94M USD
Net income4.76M USD
Diluted EPS$4.00
Rev. growth (YoY)0.00%
Balance sheet
Total cash2.61M USD
Total debt712.53K USD
Debt / equity7.74
Current ratio7.38
Book value / share$6.66
Cash flow (TTM)
Operating cash flow-2.91M USD
Levered free cash flow-8.49M USD
Shares & price
Shares outstanding1.38M
Float629.74K
Held by institutions0.00%
Beta0.00
50-day MA$4.82
200-day MA$6.32
52-week high$18.20
52-week low$3.61
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-010.800.95+18.75%2026-03-131.511.59+5.30%2025-11-180.250.33+32.00%2025-10-270.540.54+0.00%
About Advanced Biomed Inc.

Advanced Biomed Inc. is a biotechnology holding company focused on developing microfluidic biochip technologies for precision oncology applications. It integrates semiconductor technology and biotechnology to create advanced diagnostic tools, including devices such as A+Pre for automated sample preparation, AC-1000 for rare cell detection in tumor patient samples, A+SCDrop for single circulating tumor cell capture, and A+CellScan for immunostaining analysis. Corresponding microfluidic biochips and immunostaining kits like A+CTCE, A+CTCM, A+EMT, and A+CM enable the detection of circulating tumor cells and tumor markers in blood samples. These products support early cancer screening, diagnosis, staging, treatment selection, and prognosis through liquid biopsy techniques, including single-cell sorting. The company also offers the A+LCGuard kit for lung cancer early screening and operates medical clinics in China. Primary operations, research, and development occur via its Taiwan subsidiary in Tainan, with a Hong Kong entity handling China market activities including localized production and sales, and a Shanghai subsidiary managing clinical trials. Founded in 2014 and headquartered in Tainan, Taiwan, Advanced Biomed Inc. provides rapid, affordable assay products and services to cancer patients worldwide.

Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Xiaomin Chen Ph.D.
Employees
31
Headquarters
New York, NY, United States

Frequently asked questions about Advanced Biomed Inc.